• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$4.61 $0.09 (1.99%)

REAL-TIME: Last trade at

Sangamo Biosciences, Inc.

NASDAQ:SGMO

Jump to this page for:

Related Resources

Sangamo BioSciences And Collaborators Highlight Widening Applications Of ZFP Therapeutics® In Presentations At Major Gene Therapy Meeting

5/21/2012 by StockWatch

Sangamo BioSciences And Collaborators Highlight Widening Applications Of ZFP Therapeutics® In Presentations At Major Gene Therapy Meeting

5/21/2012 by PR Newswire

Sangamo BioSciences' CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)

5/16/2012 by Seeking Alpha

Sangamo Biosciences, Inc. (SGMO) Posts Q1 Loss of 14c/Share

5/2/2012 by StreetInsider.com

Sangamo BioSciences sees FY12 revenue $14-$18M, consensus $16.35M

5/2/2012 by Theflyonthewall.com

Sangamo BioSciences reports Q1 EPS (14c) , consensus (16c)

5/2/2012 by Theflyonthewall.com

Sangamo BioSciences Nominates Saira Ramasastry To The Company's Board Of Directors

4/30/2012 by PR Newswire

Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast

4/25/2012 by PR Newswire

Global Technology to host a summit

4/19/2012 by Theflyonthewall.com

Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference

4/12/2012 by StockWatch

Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference

4/12/2012 by PR Newswire

Sangamo BioSciences Announces Publication In Nature Medicine Demonstrating Use Of ZFN Technology To Engineer Safer And More Effective Cancer Treatments

4/4/2012 by Biocompare

Sangamo BioSciences (SGMO) Reports Publication of Preclinical ZFN Data

4/2/2012 by StreetInsider.com

Sangamo BioSciences reports publication of preclinical study of ZFN technology

4/2/2012 by Theflyonthewall.com

Sangamo BioSciences Announces Publication in Nature Medicine Demonstrating Use of ZFN Technology to Engineer Safer and More Effective Cancer Treatments

4/2/2012 by PR Newswire

Sangamo BioSciences Announces Presentation at Needham Healthcare Conference

3/28/2012 by PR Newswire

3 Cinderella Stocks Ready to Dance

3/20/2012 by MoneyShow.com

Sangamo BioSciences, Inc. (SGMO) Presents New Clinical Data At CROI 2012 Demonstrating Persistent Positive Effects Of ZFN Therapeutic(R) For "Functional Cure" Of HIV/AIDS

3/12/2012 by Biocompare

Sangamo Presents New Clinical Data At CROI 2012 Demonstrating Persistent Positive Effects Of ZFN Therapeutic® For

3/11/2012 by Biocompare

Sangamo BioSciences data moves company closer to HIV cure, says JMP Securities

3/9/2012 by Theflyonthewall.com

Sangamo Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic® for "Functional Cure" of HIV/AIDS

3/8/2012 by PR Newswire

New Lineup Of Drugs Reduces The Threat From Generics

2/28/2012 by Investor's Business Daily

Sangamo Biosciences (SGMO) Files $100M Mixed Shelf

2/23/2012 by StreetInsider.com

Sangamo BioSciences files $100M mixed securities shelf

2/23/2012 by Theflyonthewall.com

Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference

2/9/2012 by PR Newswire

Sangamo BioSciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript

2/8/2012 by Seeking Alpha

Sangamo Biosciences, Inc. (SGMO) Reports In-Line Q4 EPS Loss of $0.12

2/8/2012 by StreetInsider.com

Sangamo BioSciences reports Q4 EPS (12c) vs. consensus (12c)

2/8/2012 by Theflyonthewall.com

Sangamo BioSciences sees FY12 revenue $14M-$18M vs. consensus $16.23M

2/8/2012 by Theflyonthewall.com

Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results

2/8/2012 by PR Newswire

24/7 Wall St. Closing Bell (C, NEM, STX, XOM, MWW, AMZN, BRCM, AET, COCO, EPD, MAN, MPC, NOC, WHR, KTCC, SGMO, MDVN, JDAS, IXYS)

2/1/2012 by 24/7 Wall Street

Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast

2/1/2012 by PR Newswire

Shire and Sangamo BioSciences collaborate on therapeutics development

2/1/2012 by Theflyonthewall.com

Sangamo BioSciences' CEO Presents at the 30th Annual J.P. Morgan Healthcare Conference (Transcript)

1/12/2012 by Seeking Alpha

Sangamo BioSciences Announces Initiation Of Two New Phase 2 HIV Clinical Trials

1/10/2012 by Biocompare

Sangamo BioSciences initiates two new Phase 2 HIV clinical trials

1/9/2012 by Theflyonthewall.com

Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials

1/9/2012 by StockWatch

Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials

1/9/2012 by PR Newswire

Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference

1/5/2012 by PR Newswire

Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference

1/5/2012 by StockWatch
See More Articles...